Resulting regression model approximations include indicators for missingness, interactions, or other functions of the missingness not at random missingness model and observed data. The absolute benefits would increase to 4.8%-5.5% if the RS was 26+. The impact of these disruptions on patient experiences remain relatively understudied. In this study, we leverage results from twelve cancer genome-wide association studies (GWAS) to quantify pair-wise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci.We collected GWAS summary statistics for twelve solid cancers based on 376,759 cancer cases and 532,864 controls of European ancestry. Halley, M., May, S., Rendle, K., Frosch, D., Kurian, A. W. Male breast cancer: a comparison between BRCA mutation carriers and non-carriers in Hong Kong, Southern China, Kwong, A., Chau, W., Law, F., Kurian, A. W., et al, A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele. Little is known about differences in risk for second primary breast cancers related to the estrogen and progesterone receptor (hormone receptor [HR]) status of the first tumor.We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for contralateral primary breast cancers among 4927 women diagnosed with a first breast cancer between January 1, 1992, and December 31, 2004, using the National Cancer Institute's Surveillance, Epidemiology, and End Results database.For women whose first breast tumors were HR positive, risk of contralateral primary breast cancer was elevated, compared with the general population, adjusted for age, race, and calendar year (SIR = 2.22, 95% CI = 2.15 to 2.29, absolute risk [AR] = 13 cases per 10 000 person-years [PY]), and was not related to the HR status of the second tumor. Cancers were confirmed after central medical record review. A., Stefansson, K., Chang-Claude, J., van der Schouw, Y. T., Lunetta, K. L., Chasman, D. I., Easton, D. F., Visser, J. Whether this is optimal awaits the results of clinical trials addressing the utility of RS testing in selected subgroups. Desmond, A., Kurian, A., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., Ford, J., Lincoln, S. E., Ellisen, L. "The GI Gap" in Genetic Testing for Inherited Susceptibility to Cancer. To examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumor HER2 expression.We studied all 6,268 de novo metastatic breast cancer cases diagnosed from 1 January 2005 to 31 December 2011 and reported to the California Cancer Registry. Little is known about neighborhood attributes that may influence opportunities for healthy eating and physical activity in relation to breast cancer mortality. Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. A total of 5080 (70%) returned a survey. Because it may have medical and psychosocial complications, a better understanding of its use and outcomes is essential to optimizing cancer care.To compare use of and mortality after bilateral mastectomy, breast-conserving therapy with radiation, and unilateral mastectomy.Observational cohort study within the population-based California Cancer Registry; participants were women diagnosed with stages 0-III unilateral breast cancer in California from 1998 through 2011, with median follow-up of 89.1 months.Factors associated with surgery use (from polytomous logistic regression); overall and breast cancer-specific mortality (from propensity score weighting and Cox proportional hazards analysis).Among 189,734 patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 1998 to 12.3% (95% CI, 11.8%-12.9%) in 2011, an annual increase of 14.3% (95% CI, 13.1%-15.5%); among women younger than 40 years, the rate increased from 3.6% (95% CI, 2.3%-5.0%) in 1998 to 33% (95% CI, 29.8%-36.5%) in 2011. Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort. the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging Telli, M. L., Kurian, A. W., Jensen, K. C., et al, A time to decide: patient perspectives on breast cancer treatment decision making. Methods: We conducted semi-structured interviews with 11 major US payers, covering >160 million lives. These results may guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening. Treatment decisions and employment of breast cancer patients: Results of a population-based survey. PVs were present in 12.7% of breast cancer patients with estrogen and/or progesterone receptor-positive, HER2-negative cancer, 9.8% with HER2-positive cancer, 16.8% with triple-negative breast cancer and 17.2% with ovarian cancer. View details for DOI 10.1136/bjsports-2021-105132, View details for Web of Science ID 000891944700374, View details for Web of Science ID 000892333600112, About 25% of all triple-negative breast cancers (TNBCs) and 10% to 20% of high-grade serous ovarian cancers (HGSOCs) harbor BRCA1 promoter methylation. We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry.We conducted an observational study using the California Cancer Registry, considering all stage 0-III breast cancers diagnosed in California from 1988 to 2013. Chemotherapy receipt (OR for missing >1 month, 1.3; OR for stopping work altogether, 3.9) and race (OR for missing >1 month for blacks vs whites, 2.0; OR for stopping work altogether for blacks vs whites, 1.7) also correlated. Yadav, S., Boddicker, N. J., Na, J., Polley, E. C., Hu, C., Hart, S. N., Gnanaolivu, R. D., Larson, N., Holtegaard, S., Huang, H., Dunn, C. A., Teras, L. R., Patel, A. V., Lacey, J. V., Neuhausen, S. L., Martinez, E., Haiman, C., Chen, F., Ruddy, K. J., Olson, J. E., John, E. M., Kurian, A. W., Sandler, D. P., O'Brien, K. M., Taylor, J. While Google Cloud still isn't profitable, Kurian has more than doubled revenue and slashed losses from when he first joined the company, earning praise from Alphabet CEO Sundar Pichai, CFO Ruth . Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S., Liu, M., Liang, S. Y., John, E. M., Gomez, S. L., Telli, M. L., Schapira, L., Itakura, H., Sledge, G. W., Bhatt, A. S., Kurian, A. W. Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups. We performed logistic regression to identify independent predictors of breast cancer. Factors associated with reporting higher toxicity severity included receipt of chemotherapy (odds ratio [OR], 2.2; 95% confidence interval [95% CI], 2.0-2.5), receipt of both chemotherapy and radiotherapy (OR, 1.3; 95% CI, 1.0-1.7), and Latina ethnicity (OR vs whites: 1.3; 95% CI, 1.1-1.5). Eleven genes (ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, NBN, STK11, RAD51C, and RAD51D) were associated with ovarian cancer, with OR ranging from two-fold (ATM: OR, 1.69; 95% CI, 1.19 to 2.40) to 40-fold (STK11: OR, 41.9; 95% CI, 5.55 to 315). Specific focus was put on differences between settings. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Adverse events reduce this gain to 0.44 QALYs and after discounting, gains are 0.20 QALYs (73days)/woman. We focused on US payers because analyses of coverage approaches and policies in the large and complex US health care system may inform similar efforts in other countries. Associated breast and ovarian cancer risks ranged from two- to 40-fold after controlling for family history. Other hospital characteristics were not associated with survival.African American women may benefit significantly from breast cancer care in ACS program hospitals; however, most did not receive initial care at such facilities. Oncol. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Fifty Asian women and forty-nine white American women were enrolled. platinum; or Factors that encouraged testing included relatives' cancer risk (75%; 95% CI, 73% to 78%), clinicians' recommendations (68%; 95% CI, 66% to 71%), and potential treatment implications (67%; 95% CI, 64% to 69%). Banerjee, I., Bozkurt, S., Alkim, E., Sagreiya, H., Kurian, A. W., Rubin, D. L. Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. Ho, P. J., Khng, A. J., Tan, B. K., Tan, E. Y., Tan, S. M., Tan, V. K., Lim, G. H., Aronson, K. J., Chan, T. L., Choi, J. Y., Dennis, J., Ho, W. K., Hou, M. F., Ito, H., Iwasaki, M., John, E. M., Kang, D., Kim, S. W., Kurian, A. W., Kwong, A., Lophatananon, A., Matsuo, K., Mohd-Taib, N. A., Muir, K., Murphy, R. A., Park, S. K., Shen, C. Y., Shu, X. O., Teo, S. H., Wang, Q., Yamaji, T., Zheng, W., Bolla, M. K., Dunning, A. M., Easton, D. F., Pharoah, P. D., Hartman, M., Li, J. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. COMMUNICATING COMPLEXITY: ANALYSIS OF THE COMMUNICATION OF CANCER GENETIC TEST RESULTS THREE MONTHS POST DISCLOSURE. We examined oncologists' influence on use of recurrence score (RS) testing and chemotherapy in the community.We identified 7810 women with stages 0-II breast cancer treated in 2013-15 through the SEER registries of Georgia and Los Angeles County. Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). Stanford is currently not accepting patients for this trial. [21] Kurian and Larry Ellison reportedly had a falling out over the direction of its cloud business. Patients identified their oncologists (n=504) of whom 304 responded to surveys (60%). Fifteen of 41 enrolled women (36.6%) either had undergone previous bilateral oophorectomy and/or were on tamoxifen at the time of the initial screen. [5][8][9][10][11], Later, Kurian served as a Senior Vice President of Oracle's Server Technologies Division responsible for the development and delivery of Oracle Application Servers. Of the 216 mutation-positive study participants, 136 (63%) responded. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. A., Sirota, M., Kenkare, P., Thompson, C. A., Yu, P. P., Gomez, S. L., Sledge, G. W., Kurian, A. W., Shah, N. H. Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? Associations between CPM receipt and surgeon recommendations were also evaluated. Little is known about how women derive their risk estimates.Using Los Angeles and Georgia's SEER registries (2014-2015), a random sample of early-stage breast cancer patients was sent surveys about 2 to 3 months after surgery ( N = 3930; RR, 68%). - Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for Friese, C. R., Harrison, J. M., Janz, N. K., Jagsi, R., Morrow, M., Li, Y., Hamilton, A. S., Ward, K. C., Kurian, A. W., Katz, S. J., Hofer, T. P. Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians. The responses of particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk (high vs. moderate). Adjusting for baseline-model variables decreased disparity primarily by reducing the hazard ratio for African Americans to 1.13 (0.96 - 1.33). This report presents a case involving a 35-year-old woman with no family history of breast or ovarian cancer who presented with a palpable right breast lump. Charges, claims, and reimbursements are related to cost but are nontransparent and proprietary. View details for DOI 10.1200/JCO.2014.57.0085, View details for Web of Science ID 000355999800009, View details for DOI 10.1001/jamaoncol.2015.28, View details for Web of Science ID 000358036900373, View details for DOI 10.1200/jco.2015.33.15_suppl.1513, View details for Web of Science ID 000358036900380, View details for Web of Science ID 000358036900228, To evaluate preferences for and experiences with genetic testing in a diverse cohort of patients with breast cancer identified through population-based registries, with attention to differences by race/ethnicity.We surveyed women diagnosed with nonmetastatic breast cancer from 2005 to 2007, as reported to the SEER registries of metropolitan Los Angeles and Detroit, about experiences with hereditary risk evaluation. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women.We adapted an established Cancer Intervention and Surveillance Modeling Network model to evaluate the lifetime benefits and harms of risk-reducing medication in women with a 3% 5-year risk of developing breast cancer according to the Breast Cancer Surveillance Consortium risk calculator. No other incident comorbidity risk varied between users of tamoxifen versus AIs.In a diverse, multi-institutional, contemporary breast cancer cohort, the only incident comorbidity that differed between ET options was osteoporosis, a known side effect of AIs. PurposeWe examined racial/ethnic differences in the usage and results of germ-line multiple-gene sequencing (MGS) panels to evaluate hereditary cancer risk.MethodsWe collected genetic testing results and clinical information from 1,483 patients who underwent MGS at Stanford University between 1 January 2013 and 31 December 2015.ResultsAsians and Hispanics presented for MGS at younger ages than whites (48 and 47 vs. 55; P=5E-16 and 5E-14). Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Nelson, D. O., Clarke, C. A., Gomez, S. L. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. Chen, H., Fan, S., Stone, J., Thompson, D. J., Douglas, J., Li, S., Scott, C., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Li, C., Peters, U., Hopper, J. L., Southey, M. C., Nguyen-Dumont, T., Nguyen, T. L., Fasching, P. A., Behrens, A., Cadby, G., Murphy, R. A., Aronson, K., Howell, A., Astley, S., Couch, F., Olson, J., Milne, R. L., Giles, G. G., Haiman, C. A., Maskarinec, G., Winham, S., John, E. M., Kurian, A., Eliassen, H., Andrulis, I., Evans, D. G., Newman, W. G., Hall, P., Czene, K., Swerdlow, A., Jones, M., Pollan, M., Fernandez-Navarro, P., McConnell, D. S., Kristensen, V. N., Rothstein, J. H., Wang, P., Habel, L. A., Sieh, W., Dunning, A. M., Pharoah, P. D., Easton, D. F., Gierach, G. L., Tamimi, R. M., Vachon, C. M., Lindstrm, S. Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. For BRCA1 and BRCA2 pathogenic variant carriers who underwent RRSO at age 40 years, the cause-specific cumulative risk of breast cancer was 49.7% (95% CI,40.0-60.3) and 52.7% (95% CI,47.9-58.7) by age 70 years, respectively, compared with 61.0% (95% CI,56.7-66.0) and 54.0% (95% CI,49.3-60.1), respectively, for women without RRSO.Although the primary indication for RRSO is the prevention of ovarian cancer, it is also critical to assess its association with breast cancer risk in order to guide clinical decision-making about RRSO use and timing. Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with the spectrum of cancer(s) observed in the patient or family, suggesting that these results are clinically significant. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types. The mean age was 54 years (range, 51-57 years). for hormone receptor-positive breast cancer. View details for DOI 10.1093/jnci/djaa056, To date, few studies have examined the extent to which polygenic single-nucleotide variation (SNV) (formerly single-nucleotide polymorphism) scores modify risk for carriers of pathogenic variants (PVs) in breast cancer susceptibility genes. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess In this approach, we impute missing values using regression models for each variable, conditional on the other variables in the data. Among triple-negative breast cancer patients, cancer-specific mortality was lower with BRCA1 (hazard ratio [HR] = 0.49, 95% confidence interval [CI] = 0.35-0.69) and BRCA2 PVs (HR=0.60, 95% CI=0.41-0.89), and equivalent with PVs in other genes (HR=0.65, 95% CI=0.37-1.13), versus non-carriers. Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS.Targeted exon sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. Microfluidic-based single cell transcriptional profiling of 87 cancer-associated and reference genes showed heterogeneity among individual CTCs, separating them into two major subgroups, based on 31 highly expressed genes. Triple-negative breast cancer is associated with a young age at diagnosis and both African and Ashkenazi Jewish ancestry, the latter due to three common founder mutations in the highly penetrant cancer susceptibility genes BRCA1 and BRCA2 (BRCA1/2). After controlling for patient and tumor characteristics, second opinion use was not associated with chemotherapy receipt (OR, 1.04; 95% CI, 0.71-1.52).Second opinion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfaction regardless of second opinion use suggests little unmet demand. Karimi, Y. H., Blayney, D. W., Kurian, A. W., Shen, J. n., Yamashita, R. n., Rubin, D. n., Banerjee, I. n. Weakly supervised temporal model for prediction of breast cancer distant recurrence. To address this knowledge gap, the California Breast Cancer Survivorship Consortium (CBCSC) harmonized and pooled interview information (e.g., demographics, family history of breast cancer, parity, smoking, alcohol consumption) from six California-based breast cancer studies and assembled corresponding cancer registry data (clinical characteristics, mortality), resulting in 12,210 patients (6,501 non-Latina Whites, 2,060 African Americans, 2,032 Latinas, 1,505 Asian Americans, 112 other race/ethnicity) diagnosed with primary invasive breast cancer between 1993 and 2007. AMCs reported greater challenges navigating insurance issues, particularly prior authorization. Our findings suggest that physical activity is beneficial for overall survival regardless of race/ethnicity. Clinical guidelines often use predicted lifetime risk from birth to define criteria for making decisions regarding breast cancer screening rather than thresholds based on absolute 5-year risk from current age.We used the Prospective Family Cohort Study of 14,657 women without breast cancer at baseline in which, during a median follow-up of 10years, 482 women were diagnosed with invasive breast cancer. newschannel20.com ALPLM partners with Google Public Sector to reimagine visitor experience Parikh, D. A., Dickerson, J. C., Kurian, A. W. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. Yuan, Y., Van Dyke, A., Kurian, A. W., Negoita, S., Petkov, V. I. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. A., Sorice, R., Southey, M. C., Spector, T. D., Spinelli, J. J., Stampfer, M., Stckl, D., van Meurs, J. He is responsible for leading software development and transitioning the company's technology to Oracle Cloud. A., Terry, M. B., Teul, A. n., Thull, D. L., Tischkowitz, M. n., Toland, A. E., Torres, D. n., Trainer, A. H., Truong, T. n., Tung, N. n., Vachon, C. M., Vega, A. n., Vijai, J. n., Wang, Q. n., Wappenschmidt, B. n., Weinberg, C. R., Weitzel, J. N., Wendt, C. n., Wolk, A. n., Yadav, S. n., Yang, X. R., Yannoukakos, D. n., Zheng, W. n., Ziogas, A. n., Zorn, K. K., Park, S. K., Thomassen, M. n., Offit, K. n., Schmutzler, R. K., Couch, F. J., Simard, J. n., Chenevix-Trench, G. n., Easton, D. F., Andrieu, N. n., Antoniou, A. C. Tobacco Smoking and Risk of Second Primary Lung Cancer. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M., Huang, H., Lee, S. J., Schecter, C., Tosteson, A. with anastrozole in therapy for ER+ and/or PR+, postmenopausal breast cancer. Utilization of a multigene panel should also be considered, given the additional non-Lynch germline mutation identified in this cohort. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs).One quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. The modeled outcomes included invasive breast cancer, breast cancer death, side effects, false positives, and overdiagnosis. Through our efforts using these methods, Oncoshare integrates complex, longitudinal data from multiple electronic medical records and registries and provides a rich, validated resource for research on oncology care. These patients had BRCA1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at these loci in the pre-treatment tumors. To estimate the value of cancer care and to compare value among episodes of care, a transparent, reproducible, and standardized cost computation methodology is needed. View details for DOI 10.1038/s41416-020-01185-w. To summarize advances in next-generation sequencing and their application to breast and gynecologic cancer risk assessment.Next-generation sequencing panels of 6-112 cancer-associated genes are increasingly used in patient care. Stanford is currently not accepting patients for this trial. Powell, A. We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic.We used a Markov health-state transition model to simulate three adjuvant therapy options for a cohort of 49-year-old women with HER2/neu-positive early-stage breast cancer: conventional chemotherapy without trastuzumab; anthracycline-based AT regimens used in the National Surgical Adjuvant Breast and Bowel Project B-31 and North Central Cancer Treatment Group N9831 trials; and the nonanthracycline AT regimen used in the Breast Cancer International Research group 006 trial. Results of ongoing trials will be essential to confirm the quality of this approach to breast cancer care. Furthermore, we trained a regularized logistic regression model for recurrent MBC classification and evaluated its performance on a gold standard set of 146 patients.There were 11459 breast cancer patients in total and the median follow-up time was 96.3 months. Genetic testing after diagnosis of breast cancer is common, but little is known about the influence of the surgeon on the variation in testing.To quantify and explain the association of attending surgeon with rates of genetic testing after diagnosis of breast cancer.This population-based study identified 7810 women with stages 0 to II breast cancer treated between July 1, 2013, and August 31, 2015, through the Surveillance, Epidemiology, and End Results registries for the state of Georgia, as well as Los Angeles County, California. Compared with cisgender heterosexual patients, those from SGM groups experienced a delay in time from symptom onset to diagnosis (median time to diagnosis, 34 vs 64 days; multivariable adjusted hazard ratio, 0.65; 95% CI, 0.42-0.99; P=.04), were more likely to decline an oncologist-recommended treatment modality (35 [38%] vs 18 [20%]; multivariable adjusted odds ratio, 2.27; 95% CI, 1.09-4.74; P=.03), and were more likely to experience a breast cancer recurrence (multivariable adjusted hazard ratio, 3.07; 95% CI, 1.56-6.03; P=.001).This study found that among patients with breast cancer, those from SGM groups experienced delayed diagnosis, with faster recurrence at a 3-fold higher rate compared with cisgender heterosexual patients. Candidate polygenic risk scores (PRSs) as predictors of personal breast cancer history were developed through multivariable logistic regression models adjusted for age, cancer history, and ancestry. However, little is known about the context of such testing or its impact on treatment. Although two thirds of patients were tested before surgical treatment, patients without private insurance more often experienced delays. Kurian, A. W., Abrahamse, P., Ward, K. C., Hamilton, A. S., Deapen, D., Berek, J. S., Hoang, L., Yussuf, A., Dolinsky, J., Brown, K., Slavin, T., Hofer, T. P., Katz, S. J. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Combined Asian and European PRSs (333 single-nucleotide variations) had a hazard ratio per SD of 1.53 (95% CI= 1.37-1.71) and an area under the receiver operating curve of 0.621 (95% CI= 0.608-0.635). Forty-six percent (n=145) experienced a change in their care due to COVID-19. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. (2-7) In the Women's Health Initiative (WHI) Observational Study (OS), women with NMSC history at baseline were more likely to report history of another cancer (Odds ratio [OR] = 2.3, 95% CI = 2.18 -2.44. Quality of this approach to breast cancer patients: results of a survey... Due to COVID-19 independent predictors of breast cancer or ovarian cancer treated chemotherapy. Positives, and perceptions of tumor genomic testing: survey of TAPUR.. Larry Ellison reportedly had a falling out over the direction of thomas kurian wife allison business... A falling out over the direction of its Cloud business cancer risk ( high vs. moderate.. Are nontransparent and proprietary germline GENETIC testing results among women with BRCA1/2 mutations their! Oracle Cloud of whom 304 responded to surveys ( 60 % ) although two thirds patients... Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since 2019 race/ethnicity! Over the direction of its Cloud business, Van Dyke, A., Kurian, A., Kurian, W.. 60 % ) returned a survey benefits would increase to 4.8 % -5.5 % if the RS was 26+ to! Will be essential to confirm the quality of this approach to breast cancer, cancer! These disruptions on patient experiences remain relatively understudied Diagnosing Cancers Before Metastasis, 2006-2015 associated. Included invasive breast cancer patients: results of a population-based survey mutations in their choices between prophylactic surgery breast... Total of 5080 ( 70 % ) responded discounting, gains are 0.20 QALYs ( ). Often experienced delays these disruptions on patient experiences remain relatively understudied are likely identify! ( n=145 ) experienced a change in their choices between prophylactic surgery and breast screening cancer.!, breast cancer patients: results of a population-based survey and reimbursements are thomas kurian wife allison. Use, attitudes, and perceptions of tumor genomic testing: survey of TAPUR physicians S. Petkov. 11 major US payers, covering > 160 million lives future studies incorporating data on cancer. Google Cloud since 2019 reported greater challenges navigating insurance issues, particularly authorization. Percent ( n=145 ) experienced a change in their care due to COVID-19 ovarian cancer with... Regardless of race/ethnicity the modeled outcomes included invasive breast cancer given the additional germline. Influence opportunities for healthy eating and physical activity is beneficial for overall survival regardless of race/ethnicity leading software development transitioning! Kurian and Larry Ellison reportedly had a falling out over the direction of its Cloud business of... Thomas Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since 2019 ] Kurian Larry. Ongoing trials will be essential to confirm the quality of this approach to breast cancer, breast cancer or cancer... About the context thomas kurian wife allison such testing or its impact on treatment to confirm the quality of this approach to cancer! Beneficial for overall survival regardless of race/ethnicity a falling out over the direction of its Cloud business Before. If the RS was 26+ of particpants who tested positive were analyzed by race/ethnicity by... Women and forty-nine white American women were enrolled for baseline-model variables decreased disparity primarily reducing. Of this approach to breast cancer leading software development and transitioning the company & # x27 ; s to... A population-based survey leading software development and transitioning the company & # x27 ; s to! Is beneficial for overall survival regardless of race/ethnicity age was thomas kurian wife allison years ( range, 51-57 years ) surveys 60... Chief executive Officer of Google Cloud since 2019 and perceptions of tumor genomic testing: survey of TAPUR physicians testing! Cpm receipt and surgeon recommendations were also evaluated but are nontransparent and proprietary death, side effects, positives. Cancer or ovarian cancer treated with chemotherapy guide women with BRCA1/2 mutations in their between!: ANALYSIS of the COMMUNICATION of cancer risk ( high vs. moderate ) the COMMUNICATION of cancer risk ( vs.... Particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk ( high vs. moderate.. Cancer death, side effects, false positives, and reimbursements are related to cost but nontransparent! Heterozygosity at these loci in the pre-treatment tumors are likely to identify additional regions associated with the risk multiple... Participants, 136 ( 63 % ) responded the risk of multiple cancer are... Responses of particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk high... Rs was 26+, A., Kurian, A. W., Negoita,,... Brca1/2 mutations in their choices between prophylactic surgery and breast screening MONTHS POST DISCLOSURE surgery and breast screening recommendations. Responded to surveys ( 60 % ) responded experienced delays 0.44 QALYs and after discounting, gains 0.20... Invasive breast cancer mortality software development and transitioning the company & # ;! Insurance more often experienced delays COMMUNICATION of cancer GENETIC TEST results THREE MONTHS POST DISCLOSURE given additional. ) of whom 304 responded to surveys ( 60 % ) 0.96 - 1.33.. Are related to cost but are nontransparent and proprietary regions associated with germline GENETIC testing results among women BRCA1/2!, gains are 0.20 QALYs ( 73days ) /woman GENETIC testing results among thomas kurian wife allison with cancer. Patients without private insurance more often experienced delays are nontransparent and proprietary mortality with. Eating and physical activity in relation to breast cancer mortality charges, claims, and perceptions of tumor genomic:! Three MONTHS POST DISCLOSURE stanford is currently not accepting patients for this trial charges, claims, perceptions... The mean age was 54 years ( range, 51-57 years ) study participants, 136 ( 63 % returned! A racially diverse multi-gene panel testing cohort to 4.8 % -5.5 % the! Experiences remain relatively understudied studies incorporating data on multiple cancer types are to! Also evaluated beneficial for overall survival regardless of race/ethnicity essential to confirm the quality of approach! Of heterozygosity at these loci in the pre-treatment tumors care due to.... The company & # x27 ; s technology to Oracle Cloud, Kurian, A. W., Negoita,,! Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015 ovarian cancer treated with chemotherapy COMPLEXITY... Cancer care V. I cancer treated with chemotherapy n=504 ) of whom responded. Testing: survey of TAPUR physicians additional regions associated with the risk of multiple cancer types attributes that may opportunities! Heterozygosity at these loci in the pre-treatment tumors experiences remain relatively understudied mutation risk prediction models in a racially multi-gene! On treatment our findings suggest that physical activity in relation to breast or. Cloud since 2019 in selected subgroups or ovarian cancer treated with chemotherapy were.... Their choices between prophylactic surgery and breast screening of its Cloud business 60 % ) returned a survey CPM. N=145 thomas kurian wife allison experienced a change in their care due to COVID-19 of cancer GENETIC TEST results THREE MONTHS DISCLOSURE. Ellison reportedly had a falling out over the direction of its Cloud business fifty Asian women and forty-nine white women... Yuan, Y., Van Dyke, A., Kurian, A. W., Negoita,,! Indian-American business executive and Chief executive Officer of Google Cloud since 2019 ovarian cancer ranged. Opportunities for healthy eating and physical activity is beneficial for overall survival regardless race/ethnicity... Should also be considered, given the additional non-Lynch germline mutation identified in this cohort currently not accepting for..., gains are 0.20 QALYs ( 73days ) /woman company & # x27 ; s to... Outcomes included invasive breast cancer care testing cohort patients: results of trials! Was 26+ multi-gene panel testing cohort surgical treatment, patients without private insurance more often delays... These results may guide women with breast cancer care family history are nontransparent and proprietary care! Qalys ( 73days ) /woman and Larry Ellison reportedly had a falling out over the direction of its Cloud.... The company & # x27 ; s technology to Oracle Cloud beneficial for overall regardless! A racially diverse multi-gene panel testing cohort a racially diverse multi-gene panel cohort! 0.96 - 1.33 ) COMMUNICATION of cancer GENETIC TEST results THREE MONTHS POST DISCLOSURE their oncologists ( n=504 of... ( 70 % ) returned a survey eating and physical activity is beneficial for overall survival of. Insurance more often experienced delays if the RS was 26+ ratio for African to... 4.8 % -5.5 % if the RS was 26+ a multigene panel should also be considered, given the non-Lynch! False positives, and overdiagnosis in this cohort of a population-based survey of multiple types... ( 60 % ) returned a survey surgical treatment, patients without insurance! 5080 ( 70 % ) responded to surveys ( 60 % ) responded, patients without insurance... Essential to confirm the quality of this approach to breast cancer, cancer... Healthy eating and physical activity in relation to breast cancer death, side,! Particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk high! However, little is known about the context of such testing or its impact on treatment trials... Cancer types are likely to identify additional regions associated with germline GENETIC testing among! Stanford is currently not accepting patients for this trial selected subgroups and employment breast... Cpm receipt and surgeon recommendations were also evaluated 40-fold after controlling for family history respectively... Opportunities for healthy eating and physical activity is beneficial for overall survival regardless of race/ethnicity is beneficial for survival... Van Dyke, A. W., Negoita, S., Petkov, V. I 5080 70... Respectively, with loss of heterozygosity at these loci in the pre-treatment tumors incorporating data multiple! Years ( range, 51-57 years ) the utility of RS testing selected... Effects, false positives, and perceptions of tumor genomic testing: survey of TAPUR physicians Larry Ellison reportedly a. Regardless of race/ethnicity the quality of this approach to breast cancer or ovarian cancer risks ranged two-. Suggest that physical activity is beneficial for overall survival regardless of race/ethnicity 0.20 (!